|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
|
|---|---|---|---|
| Operating expenses | |||
| Research and development expenses | |||
| General and administrative | |||
| Total operating expenses | |||
| Operating loss | |||
| Other income and expense | |||
| Loss on fair value adjustment to convertible SAFE Note | |||
| Gain on long-term investment | |||
| Other expense, net | |||
| Interest expense | |||
| Interest income | |||
| Accretion of discount on investments | |||
| (Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net | |||
| Total other income and expense | |||
| Loss from operations before income taxes | |||
| Income taxes | |||
| Net loss | |||
| Net unrealized gain (loss) on investments | |||
| Total other comprehensive gain (loss) | |||
| Comprehensive loss | |||
| Net loss per common share, basic | |||
| Net loss per common share, diluted | |||
| Weighted average number of shares outstanding used in computation of net loss per common share, basic | |||
| Weighted average number of shares outstanding used in computation of net loss per common share, diluted |
Loading...
